Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Mariella Genuardi"'
Autor:
Antonio Palumbo, Alessandra Larocca, Mariella Genuardi, Katarzyna Kotwica, Francesca Gay, Davide Rossi, Giulia Benevolo, Valeria Magarotto, Federica Cavallo, Sara Bringhen, Cecilia Rus, Luciano Masini, Massimo Iacobelli, Gianluca Gaidano, Constantine Mitsiades, Kenneth Anderson, Mario Boccadoro, Paul Richardson
Publikováno v:
Haematologica, Vol 95, Iss 7 (2010)
Background Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects. In SCID/NOD mice, defibrotide showed activity in human myeloma xenografts. This phase I/II study was conducted to ident
Externí odkaz:
https://doaj.org/article/d34fa0cfc0d8491b8ace788aa98776b8
Autor:
Nicola Di Renzo, Concetta Conticello, Lucia Mastrullo, Giovanni Reddiconto, Alberto Fragasso, Daniele Scapicchio, Roberto Ria, Maria Teresa Petrucci, Gioacchino Marziano, Nicola Cascavilla, Alfredo Gagliardi, Vittorio Simeon, Silvia Mangiacavalli, Alessandro Corso, Giovanni D'Arena, Francesco Di Raimondo, Giovanna Mansueto, Lucio Catalano, Antonietta Falcone, Pellegrino Musto, Laura Cesini, Tommaso Caravita, Sara Bringhen, Giuseppe Pietrantuono, Oreste Villani, Dalila Salvatore, Mariella Genuardi, Mario Boccadoro
Publikováno v:
Annals of Hematology. 98:361-367
Therapeutic re-challenge is currently a debated issue in the field of multiple myeloma (MM), given the recent availability of several new drugs and combinations. However, very few specific evidences are available about bortezomib re-use at first rela
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc606f8fa78d1e92e986815f312c5fcf
https://doi.org/10.1007/s00277-018-3524-1
https://doi.org/10.1007/s00277-018-3524-1
Autor:
Francesca Gay, Mattia D'Agostino, Luisa Giaccone, Mariella Genuardi, Moreno Festuccia, Mario Boccadoro, Benedetto Bruno
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:471-478
Advances in understanding myeloma biology have shown that disease progression is not only the consequence of intrinsic tumor changes but also of interactions between the tumor and the microenvironment in which the cancer grows. The immune system is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bd560a7fd2e0dc6b70f9c41c0a7ea66
https://doi.org/10.1016/j.clml.2017.06.014
https://doi.org/10.1016/j.clml.2017.06.014
Autor:
Stefania Oliva, Manuela Gambella, Milena Gilestro, Vittorio Emanuele Muccio, Francesca Gay, Daniela Drandi, Simone Ferrero, Roberto Passera, Chiara Pautasso, Annalisa Bernardini, Mariella Genuardi, Francesca Patriarca, Elona Saraci, Maria Teresa Petrucci, Norbert Pescosta, Anna Marina Liberati, Tommaso Caravita, Concetta Conticello, Alberto Rocci, Pellegrino Musto, Mario Boccadoro, Antonio Palumbo, Paola Omedè
Publikováno v:
Oncotarget
// Stefania Oliva 1, * , Manuela Gambella 1, * , Milena Gilestro 1 , Vittorio Emanuele Muccio 1 , Francesca Gay 1 , Daniela Drandi 2 , Simone Ferrero 2 , Roberto Passera 3 , Chiara Pautasso 1 , Annalisa Bernardini 1 , Mariella Genuardi 1 , Francesca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2a52bd95a630259b85024f71b266515
http://hdl.handle.net/2318/1639904
http://hdl.handle.net/2318/1639904
Publikováno v:
Oncotarget
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab7d8b294054e719a44b2e8cb764c087
http://hdl.handle.net/2318/1679045
http://hdl.handle.net/2318/1679045
Publikováno v:
Expert Opinion on Drug Discovery. 9:931-943
The 26S proteasome has many important roles in the biological functions of the cells, and proteasome inhibitors have multiple and complex activities on cells. These compounds can be natural or synthesized. Most synthetic derivatives have been rationa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c08b2724f77008a7d25aa0597f19a62
https://doi.org/10.1517/17460441.2014.923838
https://doi.org/10.1517/17460441.2014.923838
Autor:
Mario Boccadoro, Pieter Sonneveld, Tommasina Guglielmelli, Elena Ponticelli, Mariella Genuardi, Antonietta Falcone, Giulia Benevolo, Chiara Nozzoli, Anna Marina Liberati, Oreste Villani, Roberto Passera, Concetta Conticello, Maria Teresa Petrucci, Elena Aghemo, Iolanda Vincelli, Fortunato Morabito, Daniele Derudas, Sara Bringhen, L De Paoli, Paola Omedè, L. De Rosa, Tommaso Caravita, Caterina Musolino, Salvatore Oliva, Alessandra Larocca, Vittorio Montefusco, Stefano Spada, A. M. Carella, Massimo Offidani, Antonio Palumbo
Publikováno v:
Leukemia, 30(6), 1320-1326. Nature Publishing Group
This phase 2 trial evaluated three low-dose intensity subcutaneous bortezomib-based treatments in patients ⩾75 years with newly diagnosed multiple myeloma (MM). Patients received subcutaneous bortezomib plus oral prednisone (VP, N=51) or VP plus cy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98264075c5db2bb001a14b977d1a8a9a
http://hdl.handle.net/11570/3093075
http://hdl.handle.net/11570/3093075
Autor:
Chiara Pautasso, Gianluca Gaidano, Nicola Cascavilla, Mariella Genuardi, Anna Marina Liberati, Giorgio La Nasa, Daniele Derudas, Alida Dominietto, Laura Maracci, Giulia Benevolo, Giovanni De Sabbata, Manuela Gambella, Sara Bringhen, Giovanni Pizzolo, Renato Zambello, Caterina Musolino, Roman Hájek, Pellegrino Musto, Antonio Palumbo, Massimo Offidani, Paola Ferrando, Donatella Zamagni, Mario Boccadoro, Ombretta Annibali, Attilio Gabbas
Publikováno v:
Publons
Introduction : Rd and MPR showed to be effective combinations in elderly newly diagnosed multiple myeloma (NDMM) patients (pts). Cyclophosphamide is a less toxic alkylating alternative agent. EMN01 is the first trial to formally compare these three d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf773d9952e2bc817dea3a7a6dcdb2b4
https://doi.org/10.1182/blood.v130.suppl_1.901.901
https://doi.org/10.1182/blood.v130.suppl_1.901.901
Autor:
Patrizia Pregno, Angelo Michele Carella, Fabrizio Esma, Roberto Mina, Concetta Conticello, Pellegrino Musto, Nicola Giuliani, Renato Zambello, Elona Saraci, Paolo Corradini, Piero Galieni, Rossella Troia, Lorenzo De Paoli, Michele Cavo, Sara Bringhen, Roberto Ria, Caterina Musolino, Elena Ponticelli, Tommaso Caravita di Toritto, Maria Teresa Petrucci, Mario Boccadoro, Anna Marina Liberati, Pieter Sonneveld, Mariella Genuardi, Stelvio Ballanti, Giovannino Ciccone, Antonio Palumbo, Massimo Offidani
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:e7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58a6b5dd596deee9a17b05b8999fe6f6
https://doi.org/10.1016/j.clml.2017.03.012
https://doi.org/10.1016/j.clml.2017.03.012
Autor:
Antonio Palumbo, Federica Cavallo, Francesca Gay, Francesco Di Raimondo, Dina Ben Yehuda, Maria Teresa Petrucci, Sara Pezzatti, Tommaso Caravita, Chiara Cerrato, Elena Ribakovsky, Mariella Genuardi, Anna Cafro, Magda Marcatti, Lucio Catalano, Massimo Offidani, Angelo Michele Carella, Elena Zamagni, Francesca Patriarca, Pellegrino Musto, Andrea Evangelista, Giovannino Ciccone, Paola Omedé, Claudia Crippa, Paolo Corradini, Arnon Nagler, Mario Boccadoro, Michele Cavo
BACKGROUND: This open-label, randomized, phase 3 study compared melphalan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantation with melphalan-prednisone-lenalidomide (MPR) and compared lenalidomide maint
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daee98591fb82d13721bfa777da9bde9
http://hdl.handle.net/11585/394357
http://hdl.handle.net/11585/394357